New England Journal of Medicine Publishes Novavax’ NanoFlu Clinical Trial Data
- NanoFluTM Phase 1/2 trial data published in a peer-reviewed letter to the editor in
The New England Journal of Medicine
- NanoFlu demonstrates significantly improved immune responses against a panel of homologous and drifted A(H3N2) influenza viruses compared to leading licensed egg-based, high-dose flu vaccine in older adults
- Phase 2 trial of quadrivalent NanoFlu expected to begin in third quarter of 2018
“We are pleased to be able to share the detailed data from the NanoFlu Phase 1/2 clinical trial with the broader scientific community,” said
- Hemagglutination inhibition (HAI) immune responses that were 28 to 64% greater against the homologous and four generations of drifted wild-type A(H3N2) influenza strains; and
- Higher HAI responses against the homologous A(H1N1) strain and comparable responses against the homologous B/
“These results showcase the potential benefit NanoFlu could have for older adults, a population challenged by poor immune responses. This population faces an urgent unmet medical need for a more effective flu vaccine, as highlighted by the severe flu season of 2017-2018,” said Dr.
About the Phase 1/2 Clinical Trial
About NanoFlu™ and Matrix M™
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by
Statements herein relating to the future of
Senior Manager, Investor & Public Relations
Source: Novavax, Inc.